Takeda Pharmaceutical Co Ltd ADR
NYSE: TAK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-04-30
Takeda Pharmaceutical Co Ltd ADR (TAK) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for TAK.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
TAK historical valuation range
Where current P/E sits in TAK's own 5Y range.
TAK intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
TAK valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 75.59x
P/S Ratio — History
Current: 0.01x
Is TAK overvalued in 2026?
Takeda Pharmaceutical Co Ltd ADR (TAK) currently trades at $16.68 per share with a market capitalization of $52,537,373,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 60/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 75.6x, above its 5-year median of 36.5x. The PEG ratio of 0.36 suggests earnings growth is outpacing the multiple, a classic sign of undervaluation.
Looking at its own history, TAK is currently trading more expensive than 83% of the last 5Y on P/E. This places it in the 83th percentile of its historical range, a zone where forward returns have typically been muted.
A standard DCF model does not produce reliable output for TAK under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: TAK trades at a fair valuation on our framework, with a Smart Value Score of 60/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is TAK overvalued in 2026?
Based on a Smart Value Score of 60/100, TAK is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is TAK's fair value?
Standard DCF is unreliable for TAK due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.
What P/E ratio does TAK trade at?
TAK trades at a P/E of 75.6x on trailing twelve-month earnings, compared to its 5-year median of 36.5x.
Is TAK a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 60/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does TAK's valuation compare to its history?
On P/E, TAK currently sits in the 83th percentile of its own 5Y range. That is historically expensive relative to where it has traded over the period.
What is TAK's Smart Value Score?
TAK's Smart Value Score is 60/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.